



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: R. GOVINDARAJAN et al.

Application No.: 09/853,619

Group Art Unit: 1614

Filed: May 14, 2001

Examiner: J. Goldberg

For: COMPOSITIONS AND METHODS  
FOR THE TREATMENT OF  
COLORECTAL CANCER

Attorney Docket No.: 9516-021

RECEIVED  
MAY 03 2002  
TECH CENTER 1600/2900

RESPONSE

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
MAY 02 2002  
TC 1700

Sir:

In response to the Office Action mailed February 1, 2002, please consider and enter the following amendments and remarks into the file of the above-captioned application.

AMENDMENTS

In the Claims

Please cancel claims 20-22 without prejudice.

REMARKS

Claims 1-19 are pending in this application. Claims 20-22 have been canceled pursuant to a restriction requirement without prejudice to Applicants' right to pursue them in one or more continuation, divisional, or continuation-in-part applications.

A. The Rejection Under 35 U.S.C. § 112 Should Be Withdrawn

On page 2 of the Office Action, claims 1-19 are rejected under the first paragraph of 35 U.S.C. § 112 as allegedly lacking enablement. In particular, it is alleged that the specification does not provide enablement for the term "pharmaceutically acceptable prodrug." This rejection is respectfully traversed for the following reasons.